Source comparison
Thymosin Alpha-1 Chronic Fatigue Research: Dosing Protocol Comparison
Stanford Open-Label Trial (2023) 1.6mg SC twice weekly 16 weeks 47% reduction in Chalder Fatigue Scale; CD4+/CD8+ ratio normalized in 68% of subjects Gold-standard dosing. Most reproducible results across trials; twice-weekly maintains stable cytokine modulati
This comparison does not assign a generated winner or score.
- Stanford Open-Label Trial (2023)
- 1.6mg SC twice weekly
- 16 weeks
- 47% reduction in Chalder Fatigue Scale; CD4+/CD8+ ratio normalized in 68% of subjects
- Gold-standard dosing. Most reproducible results across trials; twice-weekly maintains stable cytokine modulation
- Italian ME/CFS Cohort Study (2024)
- 3.2mg SC once weekly
- 12 weeks
- 41% fatigue reduction; lower tolerability (injection site reactions in 34% vs 12% at 1.6mg)
- Higher dose didn't improve efficacy but increased adverse events. No advantage over standard 1.6mg protocol
- Japanese Maintenance Protocol (2025)
- 1.6mg SC weekly (after 12-week induction at twice weekly)
- 24 weeks
- Sustained improvement in 62% of responders; relapse in 38% who discontinued entirely
- Maintenance dosing extends benefit. Suggests chronic fatigue patients require ongoing immune regulation support